Despite the increasing incidence of acute coronary syndrome (ACS) in the West, the drug development pipeline to treat it is sparse. In 2017, following their failures to meet endpoints in Phase III clinical trials, Merck’s Anacetrapib and Amgen’s AMG-899 were scrapped, seeing an end to the once much-anticipated cholesterylester transfer protein CETP inhibitors.

There are only two remaining agents in late-stage development for the treatment of ACS. Indeed, of the 112 products across all stages of development, 74% are classified as in either discovery or preclinical stages.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The early-stage ACS pipeline is dominated by small independent biopharmaceutical companies, with Big Pharma investing little in the development of new products for ACS. CSL Ltd.’s CSL-112 and Esperion Therapeutics’ ETC-1002 are both promising lipid-modifying agents in Phase III trials, and the only products on track to reach the market in the near future. The current ACS market is overcrowded with cheap generic therapies, putting pressure on Big Pharma to innovatively fulfil unmet needs to ensure profitability.